# Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy

> **NCT02216617** · PHASE1 · COMPLETED · sponsor: **Groupe Oncologie Radiotherapie Tete et Cou** · enrollment: 8 (actual)

## Conditions studied

- HNSCC

## Interventions

- **DRUG:** Taxotere, Cisplatin, Afatinib

## Key facts

- **NCT ID:** NCT02216617
- **Lead sponsor:** Groupe Oncologie Radiotherapie Tete et Cou
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-06
- **Primary completion:** 2015-07
- **Final completion:** 2015-09-15
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2017-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02216617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02216617, "Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02216617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*